9,150 Shares in Xencor, Inc. (NASDAQ:XNCR) Bought by Teza Capital Management LLC

Teza Capital Management LLC purchased a new position in shares of Xencor, Inc. (NASDAQ:XNCR) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 9,150 shares of the biopharmaceutical company’s stock, valued at approximately $210,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Xencor by 5.5% during the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company’s stock valued at $184,239,000 after purchasing an additional 418,040 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Xencor by 2.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,036,412 shares of the biopharmaceutical company’s stock valued at $92,758,000 after purchasing an additional 107,350 shares during the last quarter. TCG Crossover Management LLC boosted its stake in Xencor by 1.0% during the 4th quarter. TCG Crossover Management LLC now owns 2,452,138 shares of the biopharmaceutical company’s stock valued at $56,350,000 after purchasing an additional 25,000 shares during the last quarter. RTW Investments LP boosted its stake in Xencor by 317.9% during the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company’s stock valued at $55,218,000 after purchasing an additional 1,827,883 shares during the last quarter. Finally, BVF Inc. IL boosted its stake in Xencor by 169.3% during the 4th quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company’s stock valued at $52,596,000 after purchasing an additional 1,438,760 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Barclays dropped their price objective on Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a research note on Thursday, May 8th. Wells Fargo & Company dropped their price objective on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. William Blair assumed coverage on shares of Xencor in a research note on Monday, April 21st. They issued an “outperform” rating for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $31.00 price objective on shares of Xencor in a research note on Wednesday, April 30th. Two investment analysts have rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Xencor presently has a consensus rating of “Moderate Buy” and an average price target of $29.50.

Xencor Stock Down 7.6%

XNCR opened at $7.52 on Thursday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market cap of $535.21 million, a price-to-earnings ratio of -2.35 and a beta of 0.99. Xencor, Inc. has a twelve month low of $7.16 and a twelve month high of $27.24. The company’s 50-day moving average price is $9.88 and its two-hundred day moving average price is $16.94.

Xencor (NASDAQ:XNCR) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). The company had revenue of $32.73 million during the quarter, compared to analysts’ expectations of $23.44 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm’s revenue was up 104.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.11) earnings per share. As a group, equities analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Insider Buying and Selling at Xencor

In other Xencor news, EVP Nancy Valente sold 4,616 shares of the business’s stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the sale, the executive vice president now directly owns 49,169 shares in the company, valued at $542,334.07. The trade was a 8.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 4.76% of the company’s stock.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.